The evolving architecture of India’s clinical-trial rules, 2019-2026: a chronological appraisal and stakeholder analysis of the New Drugs and Clinical Trials Rules and their amendments

Authors

  • Vijaykumar Gawali Medical Research Department, Bhaktivedanta Hospital ad Research Institute, Mira Road East, Thane, Maharashtra, India
  • Amrita Sankhe Medical Research Department, Bhaktivedanta Hospital ad Research Institute, Mira Road East, Thane, Maharashtra, India
  • Maria Franco Medical Research Department, Bhaktivedanta Hospital ad Research Institute, Mira Road East, Thane, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3259.ijct20263765

Keywords:

Clinical trials, Drug regulation, Ethics committees, Government regulation, Patient safety, India

Abstract

India replaced the decades-old Schedule Y regime with the New Drugs and Clinical Trials (NDCT) Rules, 2019, promising a framework that would both speed up clinical research and protect the people who take part in it. Most published accounts examine one stakeholder at a time, most often the ethics committee, and treat the Rules as a static document, even though the framework has kept changing. This paper does two things at once. First, it reads the architecture of Indian clinical-trial regulation and its amendments as a single, continuous evolution: statutory timelines and deemed approval (2019), consolidation of the as-amended text (2022), a draft and then enacted registration regime for clinical research organisations (CROs) (2023-2024), digital onboarding through the SUGAM portal and a draft Indian Good Clinical Practice text aligning toward ICH E6(R3) (2025), and a 2026 cluster easing test-licence, bioavailability/bioequivalence and ethics-committee requirements, of which two amendments are now in force and two remain in draft. A consistent direction emerges toward predictability, speed and formalisation. Second, it asks whose interests that trajectory has served, reading the text alongside India-specific implementation evidence across sponsors, CROs, investigators and sites, ethics committees, participants, and the regulator. We argue that facilitation has outpaced protection. The compensation formula has lost about a third of its real value since 2013, and ethics committees carry expanded duties without commensurate capacity. We close with three concrete recommendations: revisit the compensation formula, mandate results disclosure, and resource ethics-committee oversight.

 

Metrics

Metrics Loading ...

References

Ministry of Health and Family Welfare, Government of India. New Drugs and Clinical Trials Rules, 2019. G.S.R. 227(E), dated 19 March 2019. New Delhi: Gazette of India; 2019. Available at: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/NewDrugs_CTRules_2019.pdf. Accessed on 10 January 2026.

Jesani A, Srinivasan S. New Drugs and Clinical Trials Rules, 2019: the market trumps ethics and participant rights. Indian J Med Ethics. 2019;4(2):89-91.

Singh N, Madkaikar NJ, Gokhale PM, Parmar DV. New drugs and clinical trials rules 2019: changes in responsibilities of the ethics committee. Perspect Clin Res. 2020;11(1):37-43.

Jhuria A, Nagpal D, Verma R, Mittal V, Budhwar V, Kaushik D. Navigating the evolving landscape: a review of clinical trial regulations in India. J Generic Med. 2025;21(1):22-30.

Gogtay NJ, Ravi R, Thatte UM. Regulatory requirements for clinical trials in India. Indian J Anaesth. 2017;61(3):192-9.

Drugs and Cosmetics Rules, 1945, Schedule Y (as in force before 2019). New Delhi: Government of India.

Department-related Parliamentary Standing Committee on Health and Family Welfare. 59th report on the functioning of the Central Drugs Standard Control Organisation (CDSCO). New Delhi: Rajya Sabha Secretariat; 2012.

Ranjit Roy Chaudhury Expert Committee. Report of the Expert Committee to formulate policy and guidelines for approval of new drugs, clinical trials and banning of drugs. New Delhi: MoHFW; 2013.

Supreme Court of India. Swasthya Adhikar Manch v. Union of India. Writ Petition (Civil) No. 33 of 2012. Order; 2013.

Central Drugs Standard Control Organization. Frequently Asked Questions on New Drugs and Clinical Trials. New Delhi: CDSCO; 2026. Available at: https://cdsco.gov.in/. Accessed on 10 January 2026.

Indian Council of Medical Research. National Ethical Guidelines for Biomedical and Health Research Involving Human Participants. New Delhi: ICMR; 2017.

ICMR National Institute of Medical Statistics. Clinical Trials Registry-India (CTRI): prospective registration requirement; 2026. Available at: http://ctri.nic.in/. Accessed on 10 January 2026.

Ministry of Health and Family Welfare. Amendment to the New Drugs and Clinical Trials Rules, 2019. G.S.R. 778(E); 2022.

Ministry of Health and Family Welfare. New Drugs and Clinical Trials (Amendment) Rules, 2023-First Schedule (testing methods; induced pluripotent stem cells). G.S.R. 175(E). draft notified as G.S.R. 835(E); 2022.

Ministry of Health and Family Welfare. Draft notification proposing registration of Clinical Research Organisations. G.S.R. 364(E); 2023.

Ministry of Health and Family Welfare. New Drugs and Clinical Trials (Amendment) Rules, 2024 registration of Clinical Research Organisations (rules 38A-38F). G.S.R. 581(E); 2024.

Central Drugs Standard Control Organization. Guidance on Clinical Trial Inspection. New Delhi: CDSCO; 2022.

Figer B, Gogtay NJ, Thatte UM. Compliance of Mumbai-based clinical trial sites with the Quality Council of India guidelines and evaluation of the challenges faced by the investigators. Perspect Clin Res. 2021;12(3):133-9.

Krishnan M, Sherief HS. Ethics committees in India: a study to assess the implementation of registration requirements as per New Drug and Clinical Trial Rules and the scale of standardization. Natl Med J India. 2023;36:109-11.

Ministry of Health and Family Welfare. Registration of Clinical Research Organisations via the SUGAM portal. G.S.R. 581(E); 2024.

International Council for Harmonisation. Guideline for Good Clinical Practice E6(R3): Principles and Annex 1. Geneva: ICH; 2025.

Central Drugs Standard Control Organization. Draft Good Clinical Practice Guidelines (India); 2024.

Ministry of Health and Family Welfare. Draft notifications G.S.R. 587(E) and 588(E); 2025.

Ministry of Health and Family Welfare. Corrigendum to G.S.R. 587(E). G.S.R. 810(E). revises a BA/BE sample-size condition; 2025.

Ministry of Health and Family Welfare. Draft amendment (excipient-sameness proviso; animal-toxicity exemption for BA/BE products). G.S.R. 45(E); 2026.

Ministry of Health and Family Welfare. New Drugs and Clinical Trials (Amendment) Rules, 2026-test-licence requirements (rule 52). G.S.R. 46(E); 2026.

Ministry of Health and Family Welfare. New Drugs and Clinical Trials (Second Amendment) Rules, 2026 online intimation for BA/BE of unapproved drugs for export (rule 31). G.S.R. 50(E); 2026.

Ministry of Health and Family Welfare. Draft amendment (omission of provisional certificate for ethics-committee registration; rule 17(3) omitted, 17(4) substituted-final registration on Form CT-03). G.S.R. 98(E); 2026.

Bhatt A. Conducting real-world evidence studies in India. Perspect Clin Res. 2019;10(2):51-6.

World Health Organization, Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment [Technical report]. Geneva: World Health Organization; 2014. Available at: https://www.who.int/docs/default-source/medicines/pharmacovigilance/whocausality-assessment.pdf. Accessed on 3 June 2026.

Ghooi RB. Need for revision: EC process, members’ training, and compensation formula in the New Drugs and Clinical Trials Rules 2019. Perspect Clin Res. 2022;13(3):129-31.

Vennu V, Saini PP. India’s clinical trial regulatory changes, Indian researcher’s awareness of recently changed regulations, and the impact of the New Drugs and Clinical Trial Rules: a review. Indian J Pharm Sci. 2020;82(5):726-40.

Downloads

Published

2026-10-26

How to Cite

Gawali, V., Sankhe, A., & Franco, M. (2026). The evolving architecture of India’s clinical-trial rules, 2019-2026: a chronological appraisal and stakeholder analysis of the New Drugs and Clinical Trials Rules and their amendments. International Journal of Clinical Trials, 13(4), 494–500. https://doi.org/10.18203/2349-3259.ijct20263765

Issue

Section

Review Articles